mRNA vaccine manufacturing is constrained not by scientific barriers but by capital economics and IP royalty rates that make LMIC manufacturing unviable. Current cost: $500M-$2B per new facility + 5-10% perpetual royalty payments on every dose produced. Result: all pandemic vaccine production remains concentrated in 3 wealthy countries with monopoly pricing power for future outbreaks.